Professor | Page 331 of 349

Brain Tumor :: Children’s hospital Boston neurosurgeons to perform brain tumor removal during live webcast

On Wednesday, Oct. 25, at 1:00 p.m. EDT, neurosurgeons at Children’s Hospital Boston will remove a brain tumor employing functional mapping of the cortex on a 13-year-old pediatric patient during a live Webcast. Children’s hosts three to four Webcasts annually to showcase its pioneering care and technology to specialists and referring physicians around the world, and to educate consumers on the latest and most innovative medical treatments available.

Diet :: Broccoli work to prevent cancer

After all these years, mom was right. She knew broccoli was good for you, she just didn’t know it was this good. “Everyone knows broccoli is good for you and that it contains compounds known to lessen the occurrence of some types of cancer. We want to know how these compounds work and what their specific targets may be,” says Janet V. Cross, Ph.D., Assistant Professor of Pathology at the University of Virginia School of Medicine.

Smallpox :: Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack

Mass vaccination would not be necessary in the event of a large-scale smallpox bioterrorist attack in the United States, according to a study led by researchers at Fred Hutchinson Cancer Research Center that appears online in the International Journal of Infectious Diseases.

Cancer :: Methoxyamine – new cancer therapy reverses resistance to chemotherapy

Case Western Reserve University’s Technology Transfer Office has entered a worldwide exclusive licensing agreement with TRACON Pharmaceuticals of San Diego, Calif., to develop Methoxyamine, a new cancer therapeutic that reverses cancer cell resistance to chemotherapy. Methoxyamine is a “first in class” drug that targets a specific DNA repair pathway.

Lung Cancer :: Key to lung cancer chemotherapy resistance revealed

Scientists at Johns Hopkins have discovered how taking the brakes off a ?detox? gene causes chemotherapy resistance in a common form of lung cancer. Products made by a gene called NRF2 normally protect cells from environmental pollutants like cigarette smoke and diesel exhaust by absorbing the materials and pumping them out of the cell. Another gene called KEAP1 encodes products that stop this cleansing process. But lung cancer cells sabotage the expression of these same genes to block assault from chemotherapy drugs.

Obesity :: Manhattan pharmaceuticals – oral oleoyl-estrone clinical program to include morbidly obese

Manhattan Pharmaceuticals, Inc. (Amex: MHA) today announced expansion of its oral Oleoyl-estrone (OE) clinical obesity program to include the morbidly obese. A new US Phase 2a clinical trial evaluating oral OE in morbidly obese male subjects will be initiated in October 2006. The morbidly obese population in the US is estimated to be 14 million people. OE is the Company’s orally administered product candidate in development for the treatment of obesity.

Pregnancy :: Next-generation contraceptive patch by Agile Therapeutics

Agile Therapeutics, a pharmaceutical development company focused on innovative transdermal products, is developing the next generation of contraceptive patches, one that is designed to deliver low doses of birth control hormones over a seven-day period.

Breast Cancer :: Breast cancer risk dependent upon ethnic variations in hormone levels

Researchers have known that a woman’s natural hormone levels can affect her risk of developing breast cancer. A new study from the University of Southern California (USC) has found that the natural levels of estrogens in post-menopausal women varies by ethnicity and race, and may explain the differences in the groups’ breast cancer rates. The study appears in the October issue of Cancer Epidemiology, Biomarkers & Prevention.

Smoking :: Naltrexone helps women to give up smoking

Adding the opiate blocker naltrexone to the combination of behavioral therapy and nicotine patches boosted smoking cessation rates for women by almost 50 percent when assessed after eight weeks of treatment, but made no difference for men, report researchers from the University of Chicago in the October 2006 issue of the journal Nicotine and Tobacco Research.

Diabetes :: Vision loss can be prevented in people with diabetes

The millions of Americans afflicted with Type 1 and 2 Diabetes face many potential complications,including: heart and kidney disease; nerve damage and stroke; foot and skin problems; and gastrointestinal disorders and hypoglycemia.